FDA Approves Gamida Cell’s Cell Therapy for Treating Blood Cancers
FDA announced on April 17, 2023 the approval of Israel-based cell therapy company Gamida Cell’s Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy to quicken the recovery of neutrophils, a subset of white blood cells, in the body and reduce the risk of infection.